Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 182; no. 6; pp. 927 - 930
Main Authors Varghese, Abraham M., Rawstron, Andy, Newton, Darren, Tooze, Reuben M., Munir, Talha, Dickson, Marion, Doody, Gina M., Hillmen, Peter
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.09.2018
Subjects
Aniline Compounds - pharmacology
Aniline Compounds - therapeutic use
Calcium Signaling - drug effects
Cell Survival - drug effects
Chronic lymphocytic leukemia
Hematology
Humans
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - metabolism
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Phosphorylation - drug effects
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Survival
Syk Kinase - antagonists & inhibitors
Syk Kinase - metabolism
Syk protein
Tumor Cells, Cultured
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.14884